Dear Colleagues:
As the course directors, we are thrilled to announce ACG’s new IBD School. Our first offering will be in Washington, DC, on Friday, April 7 at the Marriott Marquis Hotel. Inflammatory bowel disease (IBD) is an area of medicine that continues to see rapid developments in diagnostic and medical therapeutic options.
ACG’s IBD School is a day-long interactive educational program utilizing the combination of a clinical update on new therapeutic and monitoring approaches with an in-depth immersion in IBD case-based management discussions. Designed for the entire multi-disciplinary IBD care team, the goals of this course are to improve clinical judgment and to address the art and science of IBD management.
Clinical Focus of ACG’s IBD School
ACG’s IBD School will educate attendees in a very practical manner regarding the natural history of disease, modifiable risk factors for adverse outcomes, diagnostic and prognostic testing, and rational decision-making for medical treatment, including the latest advances in therapeutic drug monitoring and treating to achieve targets of healing or more objective control in order to change outcomes.
The program will also address changes in epidemiologic trends, advances in laboratory, radiographic, and endoscopic modalities that directly impact diagnosis and management of IBD, as well as developments in surveillance of dysplasia in ulcerative colitis and Crohn’s colitis. We will spend ample time on specific case scenarios covering some of the more challenging clinical scenarios, including the patient with C. difficile, the older patient, and the patient with refractory fistulizing disease.
We invite you to bring your entire care team and join us for ACG’s inaugural IBD School April 7 at the Marriott Marquis Hotel in Washington, DC.
ACG’s IBD School Course Co-Directors
David T. Rubin, MD, FACG & Sunanda V. Kane, MD, FACG
